2023
Epidemiology of anticoagulation for children supported by extracorporeal membrane oxygenation in the United States: A Pediatric Hospital Information System database study
Nellis M, An A, Mahmood H, Prishtina F, Hena Z, Karam O. Epidemiology of anticoagulation for children supported by extracorporeal membrane oxygenation in the United States: A Pediatric Hospital Information System database study. Perfusion 2023, 39: 536-542. PMID: 36606508, DOI: 10.1177/02676591221151027.Peer-Reviewed Original ResearchDirect thrombin inhibitorMembrane oxygenationPediatric Health Information System databaseThrombin inhibitorsHealth Information System databaseDifferent anticoagulant regimensRetrospective cohort studyUse of anticoagulationUse of bivalirudinPercent of encountersOccurrence of thrombosisRisk of thrombosisLarge administrative databaseMajority of childrenEligible encountersCardiac indicationsHeparin anticoagulationAnticoagulation regimensCohort studyMedian ageSystemic anticoagulationAnticoagulant regimensProspective studyPatient populationAdministrative databases
2021
Epidemiology of the Use of Hemostatic Agents in Children Supported by Extracorporeal Membrane Oxygenation: A Pediatric Health Information System Database Study
Nellis ME, Vasovic LV, Goel R, Karam O. Epidemiology of the Use of Hemostatic Agents in Children Supported by Extracorporeal Membrane Oxygenation: A Pediatric Health Information System Database Study. Frontiers In Pediatrics 2021, 9: 673613. PMID: 34041211, PMCID: PMC8141845, DOI: 10.3389/fped.2021.673613.Peer-Reviewed Original ResearchHemostatic blood productsECMO daysPercent of childrenBlood productsMembrane oxygenationPediatric Health Information System Database StudyPediatric Health Information System databaseHealth Information System databaseUse of TXAHospital mortality rateRetrospective observational studyU.S. children's hospitalsExtracorporeal membrane oxygenationMedian ageChildren's HospitalMedian lengthHemostatic measuresInformation System databaseObservational studyECMODatabase studyHigh riskMortality rateHemostatic agentsFactor VIIa